ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

ClinicalTrials.gov ID: NCT03638258

Public ClinicalTrials.gov record NCT03638258. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis

Study identification

NCT ID
NCT03638258
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Enrollment
331 participants

Conditions and interventions

Interventions

  • Roflumilast Cream 0.15% Drug
  • Roflumilast Cream 0.3% Drug
  • Vehicle Cream Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 20, 2018
Primary completion
May 28, 2019
Completion
May 28, 2019
Last update posted
Sep 1, 2022

2018 – 2019

United States locations

U.S. sites
20
U.S. states
11
U.S. cities
19
Facility City State ZIP Site status
Arcutis Clinical Site 35 Beverly Hills California 90212
Arcutis Clinical Site 29 Northridge California 91324
Arcutis Clinical Site 28 San Diego California 92123
Arcutis Clinical Site 27 Santa Monica California 90403
Arcutis Clinical Site 12 Miami Florida 33144
Arcutis Clinical Site 16 Sanford Florida 32771
Arcutis Clinical Site 21 Louisville Kentucky 40217
Arcutis Clinical Site 34 Clinton Township Michigan 48038
Arcutis Clinical Site 33 Detroit Michigan 48202
Arcutis Clinical Site 20 Fridley Minnesota 55432
Arcutis Clinical Site 22 New York New York 10029
Arcutis Clinical Site 14 High Point North Carolina 27262
Arcutis Clinical Site 39 Bexley Ohio 43209
Arcutis Clinical Site 15 Pittsburgh Pennsylvania 15213
Arcutis Clinical Site 19 College Station Texas 77845
Arcutis Clinical Site 37 Houston Texas 77004
Arcutis Clinical Site 13 Houston Texas 77056
Arcutis Clinical Site 23 San Antonio Texas 78213
Arcutis Clinical Site 24 Webster Texas 77598
Arcutis Clinical Site 31 Norfolk Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03638258, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 1, 2022 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03638258 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →